Edwards Lifesciences could benefit from broader Medicare eligibility for TAVR, including coverage for patients with asymptomatic severe aortic stenosis.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.